Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
Blue March: Pierre Fabre supports colorectal cancer awareness month
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Puma regains China rights to Nerlynx and amends deal with Fabre
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotech Expands Pierre Fabre License to Add Countries
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotechnology | Evaluate
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
THE FACES OF BREAST CANCER
Puma and CANBridge cancel licensing deal for $20m
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
